BiotechTube

alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Central Nervous System

Conditions

Central Nervous System

Trial Timeline

May 1, 2010 → Apr 1, 2011

NCT ID
NCT01531920

About alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol

alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol is a phase 1 stage product being developed by Eisai for Central Nervous System. The current trial status is completed. This product is registered under clinical trial identifier NCT01531920. Target conditions include Central Nervous System.

What happened to similar drugs?

4 of 20 similar drugs in Central Nervous System were approved

Approved (4) Terminated (2) Active (14)
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
✅Pregabalin + PlaceboPfizerApproved
✅Aflibercept (2.0 mg)Regeneron PharmaceuticalsApproved
✅Aflibercept (Eylea, BAY86-5321)BayerApproved
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄Leuprolide Acetate (LA)AbbViePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01531920Phase 1Completed

Competing Products

20 competing products in Central Nervous System

See all competitors
ProductCompanyStageHype Score
Placebo + MirogabalinDaiichi SankyoPhase 3
40
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
Leuprolide Acetate (LA)AbbViePhase 3
40
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35
Verteporfin + ranibizumabNovartisPhase 1/2
32